Publications
- Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed2017 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Influence of IGF1 (insulin-like growth factor 1) signaling pathway to the development of cancer diseases2016 | Faculty of Medicine in Pilsen
- High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib2015 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Science
- EGFR mutations in patients with advanced NSCLC2012 | Faculty of Medicine in Pilsen
- Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?2024 | Faculty of Medicine in Pilsen
- Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate2024 | Faculty of Medicine in Pilsen
- Pembrolizumab plus enfortumab vedotin in urothelial cancer2024 | Faculty of Medicine in Pilsen
- Klinická onkologie2023 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Second Faculty of Medicine
- Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC2023 | Faculty of Medicine in Pilsen, Central Library of Charles University, Faculty of Science
- Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study2023 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
Loading network view...
